Cheryl McDade

634 total citations
32 papers, 493 citations indexed

About

Cheryl McDade is a scholar working on Epidemiology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Cheryl McDade has authored 32 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 7 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Cheryl McDade's work include Pneumonia and Respiratory Infections (10 papers), Respiratory viral infections research (8 papers) and Hemophilia Treatment and Research (5 papers). Cheryl McDade is often cited by papers focused on Pneumonia and Respiratory Infections (10 papers), Respiratory viral infections research (8 papers) and Hemophilia Treatment and Research (5 papers). Cheryl McDade collaborates with scholars based in United States, Canada and France. Cheryl McDade's co-authors include Stephanie Earnshaw, Michael Pignone, Michele Wilson, Raymond Farkouh, Mark J. Pletcher, C. M. Kessler, Kathryn A. Phillips, Lydia B. Zablotska, Christopher N. Graham and Reto Auer and has published in prestigious journals such as Blood, Journal of General Internal Medicine and Alimentary Pharmacology & Therapeutics.

In The Last Decade

Cheryl McDade

31 papers receiving 484 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cheryl McDade United States	14	200	107	95	72	58	32	493
Andreas Heusch Germany	14	151 0.8×	102 1.0×	239 2.5×	11 0.2×	8 0.1×	37	504
J. Britto United Kingdom	12	208 1.0×	57 0.5×	19 0.2×	14 0.2×	25 0.4×	18	501
Margaret Ryan United States	11	101 0.5×	91 0.9×	94 1.0×	9 0.1×	15 0.3×	29	461
Takashi Saito Japan	12	145 0.7×	122 1.1×	28 0.3×	9 0.1×	23 0.4×	47	474
V. Taieb United Kingdom	11	112 0.6×	53 0.5×	81 0.9×	41 0.6×	46 0.8×	71	436
Jesús Aibar Spain	12	85 0.4×	28 0.3×	44 0.5×	27 0.4×	37 0.6×	31	331
G. J. P. M. Jonkers Netherlands	9	146 0.7×	95 0.9×	279 2.9×	11 0.2×	28 0.5×	13	513
Matthew D. Egberg United States	8	99 0.5×	387 3.6×	31 0.3×	12 0.2×	5 0.1×	20	613
Naomi Sacks United States	9	81 0.4×	55 0.5×	60 0.6×	23 0.3×	20 0.3×	41	289
Kathy Johnson United States	9	82 0.4×	45 0.4×	26 0.3×	10 0.1×	43 0.7×	18	288

Countries citing papers authored by Cheryl McDade

Since Specialization

Citations

This map shows the geographic impact of Cheryl McDade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheryl McDade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheryl McDade more than expected).

Fields of papers citing papers by Cheryl McDade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheryl McDade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheryl McDade. The network helps show where Cheryl McDade may publish in the future.

Co-authorship network of co-authors of Cheryl McDade

This figure shows the co-authorship network connecting the top 25 collaborators of Cheryl McDade. A scholar is included among the top collaborators of Cheryl McDade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheryl McDade. Cheryl McDade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Megías‐Vericat, Juan Eduardo, Ginés Escolar, Michele Wilson, et al.. (2025). Cost-effectiveness and cost-utility analysis of Haemate-P versus other von Willebrand disease treatments in Spain. Journal of Medical Economics. 28(1). 436–445. 1 indexed citations

Yan, Songkai, et al.. (2024). Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States. Journal of Medical Economics. 27(1). 758–765. 1 indexed citations

Perdrizet, Johnna, Kyla Hayford, Lindsay R. Grant, et al.. (2023). Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States. Infectious Diseases and Therapy. 12(5). 1351–1364. 20 indexed citations

Huang, Liping, et al.. (2023). Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease. Infectious Diseases and Therapy. 12(3). 933–950. 13 indexed citations

Wilson, Michele, et al.. (2023). Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands. Infectious Diseases and Therapy. 12(7). 1809–1821. 18 indexed citations

Zimmer, Louise, Cheryl McDade, Hadi Beyhaghi, et al.. (2022). Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care Setting. Journal of Neurotrauma. 40(7-8). 706–719. 9 indexed citations

Wilson, Michele, Cheryl McDade, Johnna Perdrizet, et al.. (2021). Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium. Infectious Diseases and Therapy. 10(3). 1765–1778. 6 indexed citations

Wilson, Michele, Matt Wasserman, Marie-Claude Breton, et al.. (2020). Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis. Infectious Diseases and Therapy. 9(2). 341–353. 11 indexed citations

Wilson, Michele, Matt Wasserman, Maarten J. Postma, et al.. (2018). Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada. Infectious Diseases and Therapy. 7(3). 353–371. 22 indexed citations

10.

Earnshaw, Stephanie, Cheryl McDade, YiFang Chu, Lisa Fleige, & John L. Sievenpiper. (2017). Cost-effectiveness of Maintaining Daily Intake of Oat β-Glucan for Coronary Heart Disease Primary Prevention. Clinical Therapeutics. 39(4). 804–818.e3. 12 indexed citations

11.

Wilson, Michele, et al.. (2017). Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. International Journal of COPD. Volume 12. 997–1008. 21 indexed citations

12.

Liu, Qifa, Lei Qin, Yixi Chen, et al.. (2016). Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. ClinicoEconomics and Outcomes Research. 8. 275–275. 3 indexed citations

13.

Earnshaw, Stephanie, Andrew P. Brogan, & Cheryl McDade. (2013). Model-Based Cost-Effectiveness Analyses for Prostate Cancer Chemoprevention. PharmacoEconomics. 31(4). 289–304. 5 indexed citations

14.

Pignone, Michael, Stephanie Earnshaw, Cheryl McDade, & Mark J. Pletcher. (2013). Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men. Journal of General Internal Medicine. 28(11). 1483–1491. 14 indexed citations

15.

Earnshaw, Stephanie, Cheryl McDade, Giovanni Zanotti, Raymond Farkouh, & David Strutton. (2012). Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infectious Diseases. 12(1). 101–101. 46 indexed citations

16.

Earnshaw, Stephanie, et al.. (2012). Economic Impact of Using Additional Diagnostic Tests to Better Select Patients With Stroke for Intravenous Thrombolysis in the United Kingdom. Clinical Therapeutics. 34(7). 1544–1558. 8 indexed citations

17.

Earnshaw, Stephanie, James M. Scheiman, A. Mark Fendrick, Cheryl McDade, & Michael Pignone. (2011). Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention. Archives of Internal Medicine. 171(3). 218–218. 45 indexed citations

18.

Kattan, Michael W., Stephanie Earnshaw, Cheryl McDade, Libby Black, & Gerald L. Andriole. (2011). Cost Effectiveness of Chemoprevention for Prostate Cancer with Dutasteride in a High-Risk Population Based on Results from the REDUCE Clinical Trial. Applied Health Economics and Health Policy. 9(5). 305–315. 6 indexed citations

19.

Earnshaw, Stephanie, Rogier Klok, Shrividya Iyer, & Cheryl McDade. (2010). Methylnaltrexone bromide for the treatment of opioid‐induced constipation in patients with advanced illness – a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics. 31(8). 911–921. 22 indexed citations

20.

Earnshaw, Stephanie, Cheryl McDade, Libby Black, Christopher F. Bell, & Michael W. Kattan. (2010). Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations. PharmacoEconomics. 28(6). 489–505. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact